Cancer drug combo trial halted early: what we know
Disease control
Terminated
This early-phase study tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…
Phase: PHASE1 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC